A detailed history of Allworth Financial LP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Allworth Financial LP holds 86 shares of DNLI stock, worth $1,996. This represents 0.0% of its overall portfolio holdings.

Number of Shares
86
Previous 889 90.33%
Holding current value
$1,996
Previous $19,000 94.74%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 25, 2024

SELL
$15.83 - $23.35 $12,711 - $18,750
-803 Reduced 90.33%
86 $1,000
Q4 2023

Jan 24, 2024

BUY
$16.2 - $23.18 $13,608 - $19,471
840 Added 1714.29%
889 $19,000
Q3 2023

Oct 31, 2023

BUY
$20.63 - $30.17 $1,010 - $1,478
49 New
49 $1,000
Q2 2022

Jul 13, 2022

BUY
$20.88 - $35.19 $167 - $281
8 New
8 $0

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.12B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.